BRAF V600E and survival benefit of anti-EGFR monoclonal antibody (mAb) therapy for metastatic colorectal cancer (mCRC): A meta-analysis.

被引：0

作者：

Sorich, Michael

Rowland, Andrew

Dias, Mafalda

McKinnon, Ross Allan

Kichenadasse, Ganessan

Wiese, Michael

Karapetis, Christos Stelios

机构：

[1] Flinders Univ S Australia, Adelaide, SA 5001, Australia

[2] Flinders Univ S Australia, Flinders Med Ctr, Adelaide, SA 5001, Australia

[3] Univ S Australia, Adelaide, SA 5001, Australia

[4] Flinders Univ S Australia, Flinders Ctr Innovat Canc, Adelaide, SA 5001, Australia

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 15期

关键词：

D O I：

10.1200/jco.2015.33.15_suppl.e14605

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

e14605

引用

页数：1

共 50 条

[31] Comment on ‘Clinical significance of BRAF non-V600E mutations on the therapeutic effects of anti-EGFR monoclonal antibody treatment in patients with pretreated metastatic colorectal cancer: the Biomarker Research for anti-EGFR monoclonal Antibodies by Comprehensive Cancer genomics (BREAC) study’
Matthew Dankner
April A. N. Rose
British Journal of Cancer, 2018, 118 : 1276 - 1277
[32] Anti-EGFR monoclonal antibodies (MAb) combined with chemotherapy in metastatic colon cancer (mCRC) patients (pts): Meta-analysis of randomized trials
Yarom, Nirit
Sella, Avishay
Gresham, Gillian
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
[33] Mechanisms of resistance to anti-EGFR monoclonal antibody treatment in metastatic colorectal cancer
Zacharenia Saridaki
Vassilis Georgoulias
John Souglakos
World Journal of Gastroenterology, 2010, 16 (10) : 1177 - 1187
[34] V600E BRAF Mutation in Vulvovaginal Melanoma Is Rare: A Study of Anti-Human BRAF V600E Monoclonal Antibody in 24 Cases
Ramineni, M.
Malpica, A.
Luthra, R.
Deavers, M. T.
Euscher, E. D.
MODERN PATHOLOGY, 2013, 26 : 293A - 293A
[35] V600E BRAF Mutation in Vulvovaginal Melanoma Is Rare: A Study of Anti-Human BRAF V600E Monoclonal Antibody in 24 Cases
Ramineni, M.
Malpica, A.
Luthra, R.
Deavers, M. T.
Euscher, E. D.
LABORATORY INVESTIGATION, 2013, 93 : 293A - 293A
[36] Mechanisms of resistance to anti-EGFR monoclonal antibody treatment in metastatic colorectal cancer
Saridaki, Zacharenia
Georgoulias, Vassilis
Souglakos, John
WORLD JOURNAL OF GASTROENTEROLOGY, 2010, 16 (10) : 1177 - 1187
[37] Proof-of-concept study of Sym004, an anti-EGFR monoclonal antibody (mAb) mixture, in patients (pts) with anti-EGFR mab-refractory KRAS wild-type (wt) metastatic colorectal cancer (mCRC)
Dienstmann, Rodrigo
Tabernero, Josep
Van Cutsem, Eric
Cervantes-Ruiperez, Andres
Keranen, Susana Rosello
Vinuales, Marta Benavent
Kjaer, Ida
Pedersen, Mikkel W.
Skartved, Niels Jorgen Ostergaard
Flensburg, Mimi F.
Horak, Ivan David
Garcia-Carbonero, Rocio
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
[38] Reply to `Comment on `Clinical significance of BRAF non-V600E mutations on the therapeutic effects of anti-EGFR monoclonal antibody treatment in patients with pretreated metastatic colorectal cancer: the Biomarker Research for anti-EGFR monoclonal Antibodies by Comprehensive Cancer genomics (BREAC) study''
Eiji Shinozaki
Takayuki Yoshino
Katsuya Tsuchihara
British Journal of Cancer, 2018, 118 : 1278 - 1279
[39] Reply to 'Comment on 'Clinical significance of BRAF non-V600E mutations on the therapeutic effects of anti-EGFR monoclonal antibody treatment in patients with pretreated metastatic colorectal cancer: the Biomarker Research for anti-EGFR monoclonal Antibodies by Comprehensive Cancer genomics (BREAC) study''
Shinozaki, Eiji
Yoshino, Takayuki
Tsuchihara, Katsuya
BRITISH JOURNAL OF CANCER, 2018, 118 (09) : 1278 - 1279
[40] Population-based screening for BRAF V600E in metastatic colorectal cancer (mCRC) to reveal true prognosis.
Chu, Jenny E.
Johnson, Benny
Morris, Van K.
Raghav, Kanwal Pratap Singh
Swanson, Lucas
Lim, Howard John
Renouf, Daniel John
Gill, Sharlene
Wolber, Robert
Karsan, Aly
Schaeffer, David F.
Kopetz, Scott
Loree, Jonathan M.
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)

← 1 2 3 4 5 →